Oxcarbazepine: Anticonvulsant profile and safety

Drugs of Today

Volumn 37, Issue 5, 2001, Pages 333-355

  Rabasseda, X ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYTOCHROME P450; OXCARBAZEPINE; OXIDOREDUCTASE;

ADOLESCENT; ADULT; ALERTNESS; ANTICONVULSANT ACTIVITY; ATAXIA; CHILD; CLINICAL TRIAL; COGNITION; DIPLOPIA; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; GRAND MAL EPILEPSY; HEADACHE; HUMAN; LIVER METABOLISM; NONHUMAN; NYSTAGMUS; PSYCHOMOTOR PERFORMANCE; REVIEW; SOMNOLENCE; TREMOR; VERTIGO;

EID: 0034940610     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2001.37.5.627955     Document Type: Review

References (119)

1. Oxcarbazepine
2. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives
3. Voltage-activated calcium channels: Targets of anti-epileptic drug therapy?
4. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents
5. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs
6. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission
7. Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters
8. Simultaneous stereoselective high-performance liquid chromatographic determination of 10-hydroxycarbazepine and its metabolite carbamazepine-10,11-trans-dihydrodiol in human urine
9. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects
10. Comparative stereoselective pharmacokinetic analysis of 10-hydroxycarbazepine after oral administration of its individual enantiomers and the racemic mixture to dogs
11. Oxcarbazepine: Mechanisms of action
12. Anticonvulsant action of oxcarbazepine, hydroxycarbamazepine, and carbamazepine against metrazol-induced motor seizures in developing rats
13. Oxcarbazepine: Preclinical anticonvulsant profile and putative mechanisms of action
14. Effects of oxcarbazepine and 10-hydroxycarbamazepine on action potential firing and generalized seizures
15. The antidepressive-like effect of oxcarbazepine: Possible role of dopaminergic neurotransmission
16. The effect of oxcarbazepine on behavioural despair and learned helplessness
17. Effect of carbamazepine, oxcarbazepine and lamotrigine on the increase in extracellular glutamate elicited by veratridine in rat cortex and striatum
18. First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite
19. Disposition of the antiepileptic oxcarbazepine and its metabolites in healthy volunteers
20. Oxcarbazepine: Preliminary clinical and pharmacokinetic studies on a new anticonvulsant
21. 14C-oxcarbazepine in man
22. Pharmacokinetic variability of oxcarbazepine in epileptic patients
23. The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers
24. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites
25. Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepine, in patients with trigeminal neuralgia
26. Induction of microsomal enzymes in rat liver by oxcarbazepine, 10,11-dihydro-10-hydroxy-carbamazepine and carbamazepine
27. Fluctuations of 10-hydroxy-carbazepine during the day in epileptic patients
28. Pharmacokinetics of oxcarbazepine in the dog
29. Rectal absorption of oxcarbazepine
30. The clinical pharmacokinetics of the new antiepileptic drugs
31. Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta
32. Pharmacokinetics of oxcarbazepine and 10-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother
33. Plasma level monitoring of oxcarbazepine in epileptic patients
34. The distribution of 10-hydroxy carbazepine in blood compartments
35. Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects
36. Enzyme induction and inhibition by new antiepileptic drugs: A review of human studies
37. Dose-dependent enzyme induction by oxcarbazepine
38. Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine
39. Oxcarbazepine (Trileptal). An effective and well tolerated new drug as first choice in treatment of focal seizures
40. Oxcarbazepine disposition: Preliminary observations in patients
41. Newer anticonvulsants: Comparative review of drug interactions and adverse effects
42. Possible interaction between oxcarbazepine and an oral contraceptive
43. Oxcarbazepine: Pharmacokinetic interactions and their clinical relevance
44. Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants
45. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women
46. Oxcarbazepine does not affect the anticoagulant activity of warfarin
47. Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases
48. Deinduction in patients on AED polytherapy when switched to oxcarbazepine (Trileptal)
49. Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine
50. Changes in unbound and total valproic acid concentrations after replacement of carbamazepine with oxcarbazepine
51. Absence of interaction between oxcarbazepine and erythromycin
52. Oxcarbazepine does not interact with cimetidine in healthy volunteers
53. Effects of dextropropoxyphene on the steady-state kinetics of oxcarbazepine and its metabolites
54. Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics. A case report
55. Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine
56. Effect of valproic acid on the pharmacokinetic profile of oxcarbazepine in the rat
57. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients
58. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: Results of a retrospective study
59. Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy
60. Monotherapy trials of new anti-epileptic drugs
61. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy
62. Oxcarbazepine in the treatment of epilepsy in children and adolescents with intellectual disability
63. Survey of 260 epileptic patients treated with oxcarbazepine (Trileptal) on a named-patient basis
64. Therapeutic experiences with 947 epileptic outpatients in oxcarbazepine treatment
65. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy
66. Oxcarbazepine in the treatment of drug-resistant epilepsy in children and adolescents: Preliminary study
67. Oxcarbazepine (GP 47 680) in the treatment of intractable seizures
68. Oxcarbazepine (GP 47.680): A possible alternative to carbamazepine?
69. Oxcarbazepine add-on for drug-resistant partial epilepsy (Cochrane review)
70. A case of simple partial seizure controlled with oxcarbazepine
71. Hyponatremia induced by oxcarbazepine in children
72. Open label pilot study of oxcarbazepine for inpatients under evaluation for epilepsy surgery
73. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy
74. Comparison of oxcarbazepine and carbamazepine: A double-blind study
75. Comparative study on the therapeutic effect of oxcarbazepine (Trileptal) and carbamazepine (Finlepsin) in children with epilepsy
76. Oxcarbazepine monotherapy for partial-onset seizures: A multicenter, double-blind, clinical trial
77. Oxcarbazepine: Double-blind, randomized, placebo-control, monotherapy trial for partial seizures
78. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group
79. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy
80. Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: One year follow-up
81. A double-blind controlled clinical trial: Oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy
82. Oxcarbazepine in the treatment of early childhood epilepsy
83. Trigeminal neuralgia: Its treatment with two new carbamazepine analogues
84. Trigeminal neuralgia
85. Oxcarbazepine: A new drug in the management of intractable trigeminal neuralgia
86. Medical management of trigeminal neuralgia
87. Drugs used in the management of trigeminal neuralgia
88. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders
89. Current perspectives in the pharmacopsychiatry of depression and mania
90. Pharmacologic agents for the treatment of acute bipolar mania
91. Oxcarbazepine, GP 47779, and spasticity
92. Oxcarbazepine and spasticity: Further observations
93. Oxcarbazepine therapy in paroxysmal kinesigenic choreoathetosis
94. Safety and efficacy of oxcarbazepine: Results of randomized, double-blind trials
95. Hyponatremia induced by oxcarbazepine
96. Oxcarbazepine-induced hyponatremia, a cross-sectional study
97. Hyponatraemia during oxcarbazepine therapy
98. Metabolic encephalopathy: Oxcarbazepine (Trileptal)-induced hyponatremia
99. Hyponatremic coma under oxcarbazepine therapy
100. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: A review
101. 12 levels during carbamazepine and oxcarbazepine therapy
102. Oxcarbazepine versus carbamazepine treatment and induction of serum lipid abnormalities
103. Thyroid and myocardial function after replacement of carbamazepine by oxcarbazepine
104. Serum sex hormone levels after replacing carbamazepine with oxcarbazepine
105. Memory and psychomotor effects of oxcarbazepine in healthy human volunteers
106. Further clinical and pharmacokinetic observations on the new anticonvulsant, oxcarbazepine
107. In vitro lymphocyte proliferation by carbamazepine, carbamazepine-10, 11-epoxide, and oxcarbazepine in the diagnosis of drug-induced hypersensitivity
108. Effects of oxcarbazepine and carbamazepine on the central nervous system: Computerised analysis of saccadic and smooth-pursuit eye movements
109. Comparison of the effects of carbamazepine and oxcarbazepine on peripheral nerve conduction
110. Anticonvulsants and breast feeding: A critical review
111. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy
112. Teratogenicity of carbamazepine-10, 11-epoxide and oxcarbazepine in the SWV mouse
113. Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy
114. New antiepileptic drugs
115. New antiepileptic drugs in epileptology
116. Treatment of epilepsy in the elderly
117. Seizures and epilepsy in the elderly
118. Practical aspects of oxcarbazepine treatment